<DOC>
	<DOCNO>NCT00226889</DOCNO>
	<brief_summary>Systemic sclerosis ( ssc ) characterise extensive tissue fibrosis . Using drug capable inhibit fibroblast activity may beneficial administrered early disease course . Thirty adult patient early SSc treat endothelin-1 antagonist bosentan 6 months.Disease progression assess .</brief_summary>
	<brief_title>Treatment Early Systemic Sclerosis Bosentan</brief_title>
	<detailed_description>Systemic sclerosis ( SSc ) characterise obliterative vasculopathy extensive fibrosis . The accumulation extracellular component extracellular matrix mostly due increase activity og tissue fibroblast . The proliferation hyperactivity fibroblast may cause enhanced production several cytokins , among endothelin-1.The activity endothelin-1 show increased circulation within skin lesion . Endothelin-1 several distinct property , among profibrotic activity , inflammatory vasoconstriction.Thus , action induce endothelin-1 may potensial target therapy SSc . Thirty patient early SSc , less 12 month duration offer six month treatment oral dual endothelin-1 antagonist bosentan . Assessment disease progression perform 3 , 6 , 9 . 12 24 month use clinical , histological immunohistochemical method .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Scleroderma , Systemic</mesh_term>
	<mesh_term>Scleroderma , Diffuse</mesh_term>
	<mesh_term>Bosentan</mesh_term>
	<criteria>Early systemic sclerosis Age &gt; 70 &lt; 18 Pregnancy Nursing HIV Hb &lt; 8.5 g/l Systolic blood pressure &lt; 85 mmHg Lack compliance Liver disease Hypersensitivity bosentan Concurrent u glibenclamide , ciclosporine A tacrolimus</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2006</verification_date>
	<keyword>Scleroderma</keyword>
	<keyword>Fibrosis</keyword>
	<keyword>Therapy</keyword>
	<keyword>Bosentan</keyword>
	<keyword>Endothelin-1</keyword>
</DOC>